Collects samples and health information from people with cancer for research
Collects tissue samples, scans and questionnaires from people with cancer for research.
Plain-language title generated from the registry record
Registry title: SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Key facts
- Where
- Athens and Ioannina, GreeceSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old is the patient who may join a trial?
Source: NCT02834884, who can take part
Where in Greece
- Athens University - Attikon University General HospitalAthens, GreeceTaking people
- HYGEIA HospitalAthens, GreeceTaking people
- NIMTS - Veterans Administration HospitalAthens, GreeceTaking people
- Ioannina University HospitalIoannina, GreeceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Organisation for Research and Treatment of Cancer - EORTC
- Trial code
- NCT02834884
- Record updated
- 24 June 2026
- Original description
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.Read full original descriptionShow less
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Patients with pathologically confirmed selected tumor types (at site or centrally); Mandatory availability of adequate human biological material (HBM); Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; Age ≥ 12 years; Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; Written informed consent according to applicable legal and ethical requirements.